ASX Stock

At Trader Dealer we understand the importance of information. You can use our handy company information finder to get key fundamental data about any company listed on the ASX.

Simply enter the stock code or the name of the company you are interested in for ASX share price information, company size, research analyst forecast, share and financial ratios, as well as a business and financial summary.

Don’t know the ASX code of the stock you want? Just click on the letter below for a full alphabetical listing.


Enter ASX Stock Code

Bookmark Page !



View all Companies by Letters

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z 


 
 

Viralytics Ltd.
Industry Group: Biotechnology / Medical Research - Biotechnology

Trade Online with Trader Dealer

Sorry, No Chart Available.

Business Summary
Viralytics Limited is engaged in the clinical advancement of its product CAVATAK and pre-clincial development of its portfolio of Oncolytic viruses. In June 2011, the Company obtained its Investigational New Drug (IND) for the use of CAVATAK allowed by the United States Food and Drug Administration (FDA). During the fiscal year ended June 30, 2011, the Company was involved in the production of the first bulk batch of clinical grade CAVATAK through an international United States-based contractor; continuation of two other Phase I trials; development of pre-clinical work in new cancer indications, and development and advancement of the its intellectual property portfolio. Clinical grade CAVATAK is required to conduct Phase II international trials. Pre-clinical work includes research in the use of CAVATAK for cancer indications, such as pancreatic and lung cancers.

Financial Summary
BRIEF: For the six months ended 31 December 2011, Viralytics Ltd.'s revenues decreased 84% to A$129K. Net loss increased from A$1.3M to A$2.7M. Revenues reflect the absence of R&D tax refund. Higher net loss reflects an increased in staff cost, a rise in Option share based expenses, higher in research, development and clinical development expenses, rise in unrealised currency gain and an increased in intellectual property.

Business Address


Suite 1B
PYMBLE, NSW 2073
Phone: 61-2-99884000
Fax: 61-2-99880999
http://www.viralytics.com

ASX Share Price Information
Current Price 0.285
Current Price Date 22/05/2012
52 Week Hi/Low 1.10 - 0.28
Avg Volume Last ten Days 0.10
ASX Company Sizing
Market Cap 21.50
Revenues 16.81
EBITDA -2.15
Net Income -2.70
Number of Employees 17
Enterprise Value 16.81
Research Analyst Forecast
Consensus Recommendation -
Target Price -
LT Growth Rate -
Projected P/E -
Sales -
EPS -
Profit -
DPS -
Share Ratios
EPS -0.04887
RPS 0.03007
BV per Share 0.15344
Cash per Share 0.08477
Cashflow per Share -0.04079
Cashflow per Share 0.00000
Financial Ratios
Gross Margin -
ROE -30.57005
Price/Sales 12.93675
P/E -
P/Book 1.85742